VERAXA Biotech AG (NASDAQ: VRXA) announced the appointment of Christoph Erkel, Ph.D., as chief scientific officer, effective immediately. Erkel, previously vice president of research and development, will lead advancement of the company’s proprietary BiTAC(R) platform technologies for the development of cancer therapies targeting solid tumors. He succeeds Rick Austin, Ph.D., who will depart following a transition period.
Erkel brings two decades of experience in antibody therapeutics, antibody engineering and preclinical development, including prior leadership roles at MorphoSys AG, where he led immuno-oncology programs focused on T-cell engagers. VERAXA said his experience managing multidisciplinary research programs will support efforts to expand the company’s oncology pipeline and advance BiTAC(R) candidates toward clinical development. The appointment signals the company's commitment to accelerating its pipeline of bispecific T cell engagers and antibody-drug conjugates (ADCs) targeting solid tumors, a significant area of unmet medical need.
This leadership change is important for investors because it positions VERAXA to potentially advance its BiTAC platform into clinical trials, which could validate the technology and lead to value creation. The BiTAC platform is designed to produce bispecific antibodies that engage T cells to attack tumor cells, a mechanism that has shown promise in hematologic cancers but remains challenging in solid tumors. With Erkel’s background in T-cell engagers at MorphoSys, the company aims to overcome these challenges and deliver novel therapies. The full press release is available at https://nnw.fm/cR1RS.
VERAXA’s pipeline includes both ADCs and BiTAC formats, with a focus on quality-by-design principles. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research. Investors can follow company updates in its newsroom at http://nnw.fm/VRXA.
The appointment comes as the biotech sector increasingly focuses on bispecific antibodies and T-cell engagers as next-generation cancer immunotherapies. By strengthening its scientific leadership, VERAXA aims to differentiate its BiTAC platform from competitors and potentially address the limitations of existing T-cell engagers, such as toxicity and limited efficacy in solid tumors. Erkel’s expertise in antibody engineering and preclinical development will be critical in advancing these programs through the critical early stages of drug development.
